Affiliation:
1. Institut National du Cancer, Boulogne Billancourt, France
2. Cemka, Bourg-la-Reine, France
3. PwC Advisory - Healthcare & Pharmaceuticals Life-Sciences, Neuilly-sur-Seine, France
Abstract
Many factors need to be considered when planning and managing a screening programme for the early detection of cervical cancer (CC). A non-systematic international review of the organisation of CC screening using high-risk human papillomavirus (HPV-HR) testing, aimed at identifying the organisational methods of these programmes, was conducted with a view to supporting the future of the French system in the context of the transition to HPV-HR testing. In countries where HPV testing has been implemented or planned, the initial reflection process has provided an opportunity to rethink the previous (cytological) screening organisation. Despite considerable differences between countries, a nationally or regionally centralised organisational model appears to be the preferred option in most countries. This model is based on a national/regional structure tasked with all invitations, reminders, follow-up and coordination, centralised laboratories integrating both biology and pathology laboratories, and a unified information system integrated with routine health management tools used by health practitioners and nurses. Besides quality considerations, grouped purchasing makes it possible to implement a public procurement policy that includes price negotiations with suppliers. Discussions around the introduction of HPV testing have resulted in most countries reviewing or creating information systems and quality assurance processes. While the WHO seems to recommend the systematic use of vaginal self-sampling, very few countries have considered this option. More and more countries are planning to implement vaginal self-sampling, but no clear organisational model has emerged from the countries where it has been implemented to date.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference38 articles.
1. Haute Autorité de Santé. Evaluation of human papillomavirus (HPV) tests for primary screening of precancerous and cancerous lesions of the cervix and the role of p16/Ki67 dual immunostaining. https://www.has-sante.fr/jcms/c_2806160/en/evaluation-of-human-papillomavirus-hpv-tests-for-primary-screening-of-precancerous-and-cancerous-lesions-of-the-cervix-and-the-role-of-p16/ki67-dual-immunostaining (accessed 18 July 2022).
2. World Health Organization. WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization, https://apps.who.int/iris/handle/10665/342741 (2021, accessed 18 July 2022).
3. HPV-based cervical cancer screening- facts, fiction, and misperceptions
4. Defining Optimal Triage Strategies for hrHPV Screen–Positive Women—An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry
5. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans